EuroNet PHL-C2试验影像数据分析提示儿童注射F-18 FDG活度可降低:一项更新EANM儿童剂量卡的提案
该研究分析EuroNet-PHL-C2试验中2082例连续[18F]FDG-PET扫描,将实际给药活度与EANM儿童剂量卡推荐值比较,并对91例低活度扫描子集进行视觉和定量图像质量评估。结果显示子集图像均具临床可用性,活度降低与肿瘤本底比相关性极弱(r=0.06),据此提出平均活度降低39%的EANM儿童剂量卡更新建议。
要点
- 在2082例[18F]FDG-PET扫描中,1960例实际活度低于EANM儿童剂量卡推荐值(中位低99.4 MBq),119例高于推荐值(中位高15.1 MBq)。
- 91例低活度子集扫描视觉评估均属临床可用,活度降低与肿瘤本底比相关性极弱(r=0.06)。
- 基于分析提出EANM儿童剂量卡更新建议,平均活度降低39%。
核心结论
- 本研究结果允许对采用常规PET/CT系统的[18F]FDG-PET/CT扫描的EANM儿童剂量卡进行保守更新。
研究设计与样本
- 在EuroNet-PHL-C2试验中共分析2082例连续[18F]FDG-PET扫描,将给药[18F]FDG活度与EANM儿童剂量卡推荐活度比较,这些扫描此前均未因图像质量差被试验参考核医学小组否决。
- 按预设标准选取91例不同患者分期时进行的[18F]FDG-PET扫描子集,标准包括仅纳入接受活度显著低于EANM儿童剂量卡推荐值的患者,并尽可能涵盖不同PET系统和成像参数。
- 由两名独立读者采用质量评分系统对子集图像质量进行视觉评估,并基于244个病灶和健康肝脏的感兴趣体积分析进行定量评估,最终据现有数据推导EANM儿童剂量卡更新建议。
主要发现
- 在1960例[18F]FDG-PET扫描中,实际活度低于EANM儿童剂量卡推荐值,中位低99.4 MBq;在119例扫描中高于推荐值,中位高15.1 MBq。
- 在91例子集分析中,所有图像数据视觉分类均为临床可用。
- 活度降低与肿瘤本底比之间仅见极弱相关性(r=0.06)。
- 由于数据集有意异质,不同成像变量范围大导致子集过小,噪声无法进行统计学可靠分析。
- 基于所呈分析提出EANM儿童剂量卡更新建议,平均活度降低39%。
关键数值与推荐
- EANM儿童剂量卡推荐活度在1960例扫描中被低于,中位低99.4 MBq;在119例扫描中被高于,中位高15.1 MBq。
- 91例子集扫描视觉评估均临床可用,活度降低与肿瘤本底比相关性r=0.06。
- 更新建议为平均活度降低39%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 由于数据集有意异质,不同成像变量范围大导致子集过小,噪声无法进行统计学可靠分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this work is to provide the currently missing evidence that may allow an update of the Paediatric Dosage Card provided by the European Association of Nuclear Medicine (EANM) for conventional PET/CT systems. METHODS: In a total of 2082 consecutive [18F]FDG-PET scans performed within the EuroNet-PHL-C2 trial, the administered [18F]FDG activity was compared to the activity recommended by the EANM Paediatric Dosage Card. None of these scans had been rejected beforehand by the reference nuclear medicine panel of the trial because of poor image quality. For detailed quality assessment, a subset of 91 [18F]FDG-PET scans, all performed in different patients at staging, was selected according to pre-defined criteria, which (a) included only patients who had received substantially lower activities than those recommended by the EANM Paediatric Dosage Card, and (b) included as wide a range of different PET systems and imaging parameters as possible to ensure that the conclusions drawn in this work are as generally valid as possible. The image quality of the subset was evaluated visually by two independent readers using a quality scoring system as well as analytically based on a volume-of-interest analysis in 244 lesions and the healthy liver. Finally, recommendations for an update of the EANM Paediatric Dosage Card were derived based on the available data. RESULTS: The activity recommended by the EANM Paediatric Dosage Card was undercut by a median of 99.4 MBq in 1960 [18F]FDG-PET scans and exceeded by a median of 15.1 MBq in 119 scans. In the subset analysis (n = 91), all image data were visually classified as clinically useful. In addition, only a very weak correlation (r = 0.06) between activity reduction and tumour-to-background ratio was found. Due to the intended heterogeneity of the dataset, the noise could not be analysed statistically sound as the high range of different imaging variables resulted in very small subsets. Finally, a suggestion for an update of the EANM Paediatric Dosage Card was developed, based on the analysis presented, resulting in a mean activity reduction by 39%. CONCLUSION: The results of this work allow for a conservative update of the EANM Paediatric Dosage Card for [18F]FDG-PET/CT scans performed with conventional PET/CT systems.
引用
- Tran-Gia J, Eberlein U, Lassmann M, et al. Analysis of image data from the EuroNet PHL-C2 trial indicates a potential reduction in injected F-18 FDG activities in children: a proposal to update the EANM Paediatric Dosage Card. Eur J Nucl Med Mol Imaging. 2023. PMID: 37728668. doi:10.1007/s00259-023-06396-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。